SCHEMBL31658284

SCHEMBL31658284

COc1cc2c(cc1OC)N(Cc1ccc(F)cc1)S(=O)(=O)c1cc(OC)c(OC)cc1-2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ HTR1A P08908 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR7 P34969 1/20 0.42
▸ HTR6 P50406 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ ACHE P22303 2/20 0.41
▸ BCHE P06276 1/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ HDAC1 Q13547 2/20 0.39
▸ HDAC2 Q92769 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ABCB1 P08183 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31658297 0.90 CYP1A2 (0.44) CA12CA1CA9HTR1ADRD2
SCHEMBL31658259 0.90 CA12 (0.42) CA12CA1CA9HTR1ADRD2
SCHEMBL31658257 0.89 GAA (0.42) HTR1ADRD2HTR2AHTR7HTR6
SCHEMBL31658296 0.87 CA12 (0.46) CA12CA9HTR1ADRD2HTR2A
SCHEMBL31658317 0.87 CA12 (0.42) CA12CA1CA9HTR1ADRD2
SCHEMBL31662739 0.86 HCRTR1 (0.41) CA12CA1CA9HTR1ADRD2
SCHEMBL31658289 0.84 CA12 (0.49) CA12CA1CA9HTR1ADRD2
SCHEMBL31658292 0.82 CA12 (0.42) CA12CA1CA9HTR1ADRD2
SCHEMBL31658310 0.81 HCRTR1 (0.39) CA12CA1CA9HTR1ADRD2
SCHEMBL31658291 0.78 CA12 (0.49) CA12CA1CA9TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149586-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF FATTY LIVER DISEASE SCANDIEDGE THERAPEUTICS AB (SE) 2025-07-17 — — WO disclosed
EP-4585216-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF FATTY LIVER DISEASE ScandiEdge Therapeutics AB (SE) 2025-07-16 — — EP disclosed
Send feedback